BioNTech
randomized phase trial in adjuvant cancer | BioNTech
Company
Deck Type
Sector
Industry
Deck date
August 2021
Slide
30 of 43
Related slides by other companies
Matinas BioPharma
Investor Presentation
August 2023
phase aspergillosis study preliminary design subject to agreement | Matinas BioPharma
Matinas BioPharma
Investor Presentation
May 2023
phase aspergillus study preliminary design subject to agreement teer | Matinas BioPharma
ATAI
Investor Presentation
March 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
Erasca
Investor Presentation
August 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights